Sharps Technology and Valneva Compared in Head-to-Head Analysis

Analysts see more upside potential in Valneva stock compared to Sharps Technology.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Valneva (NASDAQ:VALN) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but research analysts believe Valneva is the more favorable stock based on its stronger consensus rating and higher potential upside. While Sharps Technology has lower revenue, it has higher earnings than Valneva. Valneva also trades at a lower price-to-earnings ratio, making it more affordable currently.

Why it matters

This analysis provides investors with a comparative look at two small-cap medical companies to help inform investment decisions. The findings highlight key differences in factors like valuation, profitability, and analyst sentiment that could sway investors toward one stock over the other.

The details

The analysis compares Valneva and Sharps Technology across several metrics, including valuation, risk, profitability, institutional ownership, earnings, dividends, and analyst recommendations. Valneva has a higher consensus target price and stronger analyst ratings, while Sharps Technology has lower revenue but higher earnings. Valneva also trades at a lower price-to-earnings ratio.

  • The analysis was published on March 6, 2026.

The players

Valneva SE

A specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases.

Sharps Technology, Inc.

A medical device company that researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between two small-cap medical companies, Valneva and Sharps Technology, to help investors assess which stock may be the better investment option based on factors like valuation, profitability, and analyst sentiment.